Abcam, ab265475, Human FHL2 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
FHL2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FHL2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The FHL2 protein also known as Four and a Half LIM Domains Protein 2 plays an important role in cellular mechanics. Its molecular mass is approximately 32 kDa. FHL2 is expressed in various tissues with significant presence in cardiac and skeletal muscles as well as the liver. It is involved in the regulation of gene expression by binding to other proteins and DNA through its LIM domains. This ability allows FHL2 to influence cellular structures and functions integrally.
Biological function summary
The FHL2 protein serves critical functions in muscle development and differentiation. It operates as part of a multiprotein complex that interacts with cytoskeletal components contributing importantly to muscle cell adhesion and communication. Moreover FHL2 engages in transcriptional regulation and acts as a coactivator or corepressor of specific transcription factors influencing gene expression patterns relevant to muscle function and maintenance.
Pathways
The FHL2 protein plays significant roles in Wnt and MAPK signaling pathways. In the Wnt signaling pathway FHL2 regulates the transcriptional activity of beta-catenin an essential component of the pathway involved in cell growth and differentiation. Additionally FHL2 contributes to the MAPK signaling pathway by influencing interactions between upstream regulators and downstream targets modulating cellular responses to external stimuli. Through these pathways FHL2 interacts with various proteins including GATA4 and TEF-1 which are vital for its regulatory functions.
FHL2 has associations with certain cancers like prostate cancer and cardiomyopathy. In prostate cancer FHL2 overexpression leads to increased tumor progression and is often linked to androgen receptors promoting malignant transformation. In cardiomyopathy alterations in FHL2 expression affect heart muscle integrity and function sometimes in conjunction with interactions involving desmin an important structural protein. Understanding FHL2's connections to these diseases offers insights into potential therapeutic targets.